Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Genomic Health Inc (GHDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 1,116,815
  • Shares Outstanding, K 34,070
  • Annual Sales, $ 327,870 K
  • Annual Income, $ -13,920 K
  • 36-Month Beta 0.46
  • Price/Sales 3.41
  • Price/Cash Flow 0.00
  • Price/Book 7.04

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.08 +9.61%
on 04/13/17
33.30 -0.99%
on 04/27/17
+1.28 (+4.04%)
since 03/28/17
3-Month
26.54 +24.23%
on 01/31/17
33.30 -0.99%
on 04/27/17
+5.67 (+20.77%)
since 01/27/17
52-Week
23.57 +39.88%
on 05/19/16
33.96 -2.92%
on 11/14/16
+5.58 (+20.37%)
since 04/28/16

Most Recent Stories

More News
Zacks.com featured highlights: Cabot Oil & Gas, Cardiovascular Systems, Fortress Transportation and Infrastructure, Genomic Health and Par Pacific Holdings

Zacks.com featured highlights: Cabot Oil & Gas, Cardiovascular Systems, Fortress Transportation and Infrastructure, Genomic Health and Par Pacific Holdings

GHDX : 32.97 (+0.58%)
PARR : 16.43 (+0.12%)
FTAI : 14.99 (-0.93%)
COG : 23.32 (-3.32%)
CSII : 29.85 (-0.07%)
A Company's First Profit Can Mean Big Profits to Investors

A Company's First Profit Can Mean Big Profits to Investors

PARR : 16.43 (+0.12%)
GHDX : 32.97 (+0.58%)
FTAI : 14.99 (-0.93%)
COG : 23.32 (-3.32%)
CSII : 29.85 (-0.07%)
A Company's First Profit Can Mean Big Profits to Investors

A Company's First Profit Can Mean Big Profits to Investors

PARR : 16.43 (+0.12%)
GHDX : 32.97 (+0.58%)
FTAI : 14.99 (-0.93%)
COG : 23.32 (-3.32%)
CSII : 29.85 (-0.07%)
Genomic Health's GPS Predicts Metastatic Prostate Cancer

Genomic Health, Inc. (GHDX), a global cancer company, recently unveiled positive results regarding Oncotype DX Genomic Prostate Score (GPS).

OSUR : 13.16 (+1.08%)
GHDX : 32.97 (+0.58%)
ZLTQ : 56.48 (unch)
INGN : 82.61 (-1.18%)
Oncotype DX® Predicts 10-year Risk of Developing Metastatic Prostate Cancer in Low- and Intermediate-risk Patients

Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of new results from a large multi-center validation study, which confirmed that the Oncotype DX® Genomic Prostate Score(TM) (GPS) is...

GHDX : 32.97 (+0.58%)
Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results

Genomic Health, Inc. (Nasdaq: GHDX) today announced the publication of results from the National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER) Registry in the peer-reviewed...

GHDX : 32.97 (+0.58%)
Genomic Health's Cancer Test Business Strong, Expenses High

On Mar 20, we issued an updated research report on Redwood City, CA-based Genomic Health Inc. (GHDX), a leading global cancer company with a focus on advanced molecular diagnostics.

GHDX : 32.97 (+0.58%)
BVX : 2.65 (-1.12%)
RMD : 69.13 (-5.11%)
INGN : 82.61 (-1.18%)
Genomic Health (GHDX) Up 2.1% Since Earnings Report: Can It Continue?

Genomic Health (GHDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

GHDX : 32.97 (+0.58%)
Genomic Health's Breast Recurrence Test Data Encouraging

Genomic Health, Inc. (GHDX), a leading molecular diagnostics company, recently presented results from 15 Oncotype DX Breast Recurrence Score studies.

GHDX : 32.97 (+0.58%)
BVX : 2.65 (-1.12%)
RMD : 69.13 (-5.11%)
INGN : 82.61 (-1.18%)
Multiple Presentations at 15th St. Gallen International Breast Cancer Conference Demonstrate Significant Impact of Oncotype DX Breast Recurrence Score® in Reducing Burden and Cost of Chemotherapy

Genomic Health, Inc. (Nasdaq: GHDX) today announced results from 15 Oncotype DX Breast Recurrence Score® studies conducted in 12 countries that provide real-world evidence of the test's ability to change...

GHDX : 32.97 (+0.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Genomic Health, Inc. is a life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. It launched its first test, Oncotype DX, which has been shown to predict...

See More

Support & Resistance

2nd Resistance Point 33.49
1st Resistance Point 33.14
Last Price 32.97
1st Support Level 32.59
2nd Support Level 32.39

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.